Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Arcus Biosciences, Inc. (NYSE:RCUS)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Arcus Biosciences, Inc. (NYSE:RCUS) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 17,631 shares of the company’s stock, valued at approximately $138,000.

Several other institutional investors have also modified their holdings of the stock. Lazard Asset Management LLC lifted its stake in shares of Arcus Biosciences by 3,321.3% during the 4th quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock worth $93,000 after acquiring an additional 6,078 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of Arcus Biosciences by 40.5% during the 1st quarter. Exchange Traded Concepts LLC now owns 13,922 shares of the company’s stock worth $109,000 after acquiring an additional 4,013 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its stake in shares of Arcus Biosciences by 21.3% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 15,381 shares of the company’s stock worth $121,000 after acquiring an additional 2,700 shares during the last quarter. Teacher Retirement System of Texas lifted its stake in shares of Arcus Biosciences by 21.9% during the 1st quarter. Teacher Retirement System of Texas now owns 18,227 shares of the company’s stock worth $143,000 after acquiring an additional 3,275 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Arcus Biosciences by 54.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 18,405 shares of the company’s stock worth $144,000 after acquiring an additional 6,453 shares during the last quarter. 92.89% of the stock is owned by institutional investors.

Analyst Ratings Changes

RCUS has been the subject of a number of research analyst reports. Wedbush reissued an “outperform” rating and set a $33.00 price target on shares of Arcus Biosciences in a research note on Wednesday, May 7th. Morgan Stanley decreased their price target on Arcus Biosciences from $24.00 to $22.00 and set an “overweight” rating for the company in a research note on Friday, May 9th. Barclays decreased their target price on Arcus Biosciences from $29.00 to $14.00 and set an “overweight” rating for the company in a research report on Wednesday, April 23rd. The Goldman Sachs Group decreased their target price on Arcus Biosciences from $15.00 to $13.00 and set a “neutral” rating for the company in a research report on Thursday, May 8th. Finally, Wells Fargo & Company decreased their target price on Arcus Biosciences from $29.00 to $26.00 and set an “overweight” rating for the company in a research report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Arcus Biosciences presently has an average rating of “Moderate Buy” and an average price target of $21.29.

Arcus Biosciences Trading Up 3.5%

Shares of NYSE RCUS opened at $9.55 on Wednesday. The company has a quick ratio of 5.37, a current ratio of 5.37 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $9.15 and a two-hundred day simple moving average of $9.53. The firm has a market cap of $1.01 billion, a PE ratio of -2.28 and a beta of 0.89. Arcus Biosciences, Inc. has a twelve month low of $6.50 and a twelve month high of $18.98.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.12). Arcus Biosciences had a negative net margin of 258.94% and a negative return on equity of 70.58%. The company had revenue of $28.00 million during the quarter, compared to analysts’ expectations of $38.61 million. During the same quarter in the prior year, the business posted ($0.05) earnings per share. The company’s revenue was down 80.7% compared to the same quarter last year. Analysts expect that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.